CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that cannot be cured with standard treatment anymore (or you couldn’t tolerate it).
- Your cancer type must match one of these groups: colorectal, pancreatic, or one of several other listed cancers.
- Your scans show measurable, metastatic disease from imaging done within the last 6 weeks.
- Your general health is good enough for study treatment (age 18+; performance status 0–1, or 2 only by special approval).
- Your blood and organ tests are adequate: white blood cells, hemoglobin, platelets, and liver/kidney labs must be within required ranges.
- You must not have certain major recent problems (like recent heart attack, uncontrolled infections, or certain lung conditions) and must be able to take oral study medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
This trial tests if adding a new drug (MP0317) to standard chemoimmunotherapy helps people with advanced bile duct cancer. It's for patients who haven't had treatment yet, except for certain past adjuvant therapy.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Hear when a new Advanced Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.